Associate Professor, Internal Medicine, Washington University School of Medicine
Oncology
Dr. Peter Westervelt, MD
|
|
Give Review
Peter Westervelt works in the field of Oncology. He went to medical school at Washington University School of Medicine in St. Louis. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Peter Westervelt is a published doctor. He has 73 publications published. The most current publication "Role of HIV-1 envelope V3 loop cleavage in cell tropism." He accepts Medicare.
Publications
- Peri-transplant serum albumin decline predicts subsequent severe Acute graft-versus-host disease following mucotoxic myeloablative conditioning.
- Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
- Acute myeloid leukemia presenting with extensive bone marrow necrosis, leukemia cutis and testicular involvement: successful treatment with allogeneic hematopoietic st...
- Genomic analysis of germline and somatic variants in familial myelodysplasia/Acute myeloid leukemia.
- Myelodysplastic syndromes, version 2.2015.
- Role of TP53 mutations in the origin and evolution of therapy-related Acute myeloid leukaemia.
- A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
- Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for Acute graft-versus-host disease: BMT CTN 0802.
- Clonal architecture of secondary Acute myeloid leukemia defined by single-cell sequencing.
- Haploidentical transplantation using G-CSF-mobilized T-Cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated wi...
- A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
- Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
- Phase I study of oral clofarabine consolidation in adults aged 60 and older with Acute myeloid leukemia.
- Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Co...
- Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
- A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
- Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.
- Dose intensification of daunorubicin and cytarabine during treatment of adult Acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
- Clonal evolution in relapsed Acute myeloid leukaemia revealed by whole-genome sequencing.
- Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.
- Myeloid growth factors.
- Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and Acute myeloid leukemia: A phase I study.
- Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem Cell transplanta...
- Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.
- Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
- Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B Cell malignancies: CALGB 109901.
- NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.
- DNMT3A mutations in Acute myeloid leukemia.
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with Acute myeloid leukemia.
- Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem Cell transplant recipients.
- Salvage therapy for Acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
- Recurring mutations found by sequencing an Acute myeloid leukemia genome.
- Acquired copy number alterations in adult Acute myeloid leukemia genomes.
- A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
- Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adult...
- Allo-SCT conditioning for myelodysplastic syndrome and Acute myeloid leukemia with clofarabine, cytarabine and ATG.
- DNA sequencing of a cytogenetically normal Acute myeloid leukaemia genome.
- Myelodysplastic syndromes.
- Impact of mobilization and remobilization strategies on achieving sufficient stem Cell yields for autologous transplantation.
- Rapid mobilization of functional donor hematopoietic Cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
- Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo Acute myeloid leukemia.
- Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
- Myeloid growth factors. Clinical practice guidelines in oncology.
- Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10.
- Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes?
- Cellular immune therapy for refractory Cancers: novel therapeutic strategies.
- A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory Acute graft-versus-host disease.
- High-penetrance mouse model of Acute promyelocytic leukemia with very low levels of PML-RARalpha expression.
- High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem Cell transplantation for patients with non-Hodgkin''s lymphoma.
- Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem Cells with low ...
- Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with Acute promyelocytic leukemia.
- Pharmacokinetic study of infusional valspodar.
- Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem Cell transplantation.
- Low incidence of transplantation-related Acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose ...
- Treatment of steroid-resistant Acute graft-versus-host disease with anti-thymocyte globulin.
- Sudden death among patients with Acute promyelocytic leukemia treated with arsenic trioxide.
- Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous Leukemia: late complications of therapy.
- Acquired, nonrandom chromosomal abnormalities associated with the development of Acute promyelocytic leukemia in transgenic mice.
- Pathologic, cytogenetic and molecular assessment of Acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
- Adverse side-effects associated with G-CSF in patients with chronic myeloid Leukemia undergoing allogeneic peripheral blood stem cell transplantation.
- Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
- A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven Acute promyelocytic leukemia.
- Seed versus soil: the importance of the target cell for transgenic models of human Leukemias.
- Role of HIV-1 envelope V3 loop cleavage in Cell tropism.
- Identification of HIV1 determinants for T lymphoid Cell line infection.
- HIV-1 V3 envelope sequences required for macrophage infection.
- Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations.
- Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak.
- Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.
- Formation of noninfectious HIV-1 virus particles lacking a full-length envelope protein.
- Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.
- Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants.
Schools
Washington Center School of Medicine
Barnes Jewish Hospital S Campus
Washington UB JhSlch Conc
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Washington University -
Washington University - Barnes-Jewish Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1043292246 | |
| NPPES Provider LastName | WESTERVELT | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1314.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 73.0 | |
| Percent Opioid Claims | 5.56 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1043292246 |
| Last Name Of The Provider | WESTERVELT |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
|
Dr. Mary M. Klix, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel Picus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Moriconi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd A. Fehniger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Albert C. Lockhart, MD |
|
Dr. Christos N. Papageorgiou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Iskra Pusic, MD
This Doctor is OpenDoctor Recommended.
|